ISWTC Boston Summer Panel: From China Speed to Global Value: How China-Origin Innovation Is Reshaping Global Biopharma
China biotech is moving from “fast follower” to a meaningful source of global biopharma innovation, reshaping how global pharma sources assets, how biotechs build value, how investors assess opportunities, and how cross-border BD deals are structured.
This in-person, closed-door discussion will bring together leaders in cross-border transactions, biotech R&D, venture investment, and Wall Street analysis to discuss what China-origin innovation means for the global biopharma ecosystem.
🎤 Featured Panelists
Hemmie Chang
Partner, Arnold & Porter
Leading advisor on global life sciences licensing, IP transactions, and strategic partnerships with over $20B in completed deals.
Roger Song, MD, MBA, CFA
Senior Equity Research Analyst, Jefferies
Bringing nearly 20 years of experience across equity research, venture capital, consulting, and the biopharma industry.
Kate Zhang, PhD
Venture Partner, Tailwinds Venture
Former CSO at U.S. biotech Hopewell Tx, with progressive leadership experience at Editas Medicine, Genzyme, and Sanofi. She brings deep expertise in CRISPR, translational science, and next-generation therapeutic platforms.
Sabrina Yang, PhD
Vice President, Global Initiatives, Flagship Pioneering
Co-founder of multiple Flagship-launched biotech companies, with extensive experience in company creation and now leading Flagship’s China strategy and cross-border initiatives.
💡 Discussion Topics
🔹 China's growing impact on global biopharma innovation
🔹 Key differences between U.S. and China biotech ecosystem
🔹 Collaboration and competition between China and the West in a more complex geopolitical environment
🔹 Career opportunities and challenges emerging from this new wave
👤 Who Should Attend (limited seats)
Scientists • Entrepreneurs • Investors • Any biopharma professionals interested in the future of our industry
Free for newsletter paid subscriber
Please check our newsletter paid content for coupon